An interventional study of VA-ECMO in Acute Myocardial Infarction and Cardiogenic Shock, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-14.
Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 62 studies in Shock, Cardiogenic with a site in France — 20 open to participants now, 21 under way, 2 of them phase 3. Shock, Cardiogenic · France.
Among the 62 studies in Shock, Cardiogenic with a site in France, this one is the 4th largest by planned enrollment of the 25 interventional ones that give a count, is one of 6 that started in 2021, is one of 13 with no phase, reaches primary completion later than 7 of the 20 other live ones, and was the 25th registered.
297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.
Browse Shock, Cardiogenic studies →20 of the 62 studies in Shock, Cardiogenic with a site in France are open now. Recruiting first, the newest first:
CMC Ambroise Paré · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
University Hospital, Strasbourg, France · Sites in France
Ages 18+
Centre Hospitalier Universitaire, Amiens · Sites in France
Ages 18+
4TEEN4 Pharmaceuticals GmbH · Sites in France, Armenia, Belgium and 6 more countries
Ages 18–80
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
62 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 6 · Phase 4 3
First in 2005; this study’s year is marked. 6 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 80 across 133 interventional studies indexed under Shock, Cardiogenic.
Median enrollment 164 across the 25 interventional studies, 150 across the 37 observational. Of the 28 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 62 have an industry lead sponsor. The 10 most frequent:
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
Assistance Publique - Hôpitaux de Paris has 8 studies filed under Shock, Cardiogenic — fewer than ten, so there is no comparison to draw.
8 of the studies in Shock, Cardiogenic with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04020263Phase 3Pr Bruno LEVYEffect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock | 2027-02-03 |
| NCT05879276Phase 3Central Hospital, Nancy, FranceEffect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function. | 2027-03-16 |
| NCT068327224TEEN4 Pharmaceuticals GmbHA Phase 1b/2a Trial to Evaluate Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care. | 2026-12-30 |
| NCT07354568Centre Hospitalier Universitaire, AmiensPrognosis of Patients With Mixed Cardiogenic-Vasoplegic Shock | 2027-01-01 |
| NCT07027202Assistance Publique - Hôpitaux de ParisEarly Preventive Left Ventricle Unloading After VA-ECMO for Refractory Cardiogenic Shock | 2027-07 |
Add all 8 to your calendar (.ics) → With an account.
Among the 62 studies in Shock, Cardiogenic with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Data from case series and large retrospective trials suggest that the early treatment of cardiogenic shock AMI patients with the association of VA-ECMO and IABP may significantly decrease mortality, which is still unacceptably high nowadays (40-50% at 30 days).
An important benefit for the patients randomized to the ECMO arm is expected and the risk-to-benefit ratio is expected to be in favor of the experimental treatment arm.
Scientific background
The ANCHOR trial is therefore designed to test the hypothesis that VA-ECMO support associated with IABP results in improved outcomes in comparison with optimal medical treatment alone in patients with AMI and cardiogenic shock. An ethical rescue option to VA-ECMO will however be provided to control patients with cardiogenic shock refractory to conventional medical treatment since recent data suggested survival up-to 50% with ECMO support in this setting.
Main objective - To determine if early VA-ECMO combined with IABP support and optimal medical treatment would improve the outcomes of patients with acute myocardial infarction complicated by cardiogenic shock as compared with optimal medical treatment alone.
Scope of the study
Should such a person be absent, eligible patients will be randomized according to the specifications of emergency consent and the patient will be asked to give his/her consent for the continuation of the trial when his/her condition will allow.
Randomization will be possible in centers with robust experience in the management of AMI and cardiogenic shock but no on-site ECMO capability providing that an ECMO retrieval team from the nearest ECMO center can establish ECMO no later than 2 hours after randomization.
Before randomization, physicians at the non-ECMO center will check that the ECMO team is immediately available and that an ICU/CCU bed is available at the ECMO center. Thereafter, if the patient is randomized to the ECMO arm, the mobile ECMO retrieval team will travel to the center, initiate VA-ECMO and will rapidly transfer the patient on VA-ECMO to the ECMO center.
Description of experimental ECMO + IABP Arm
Description of conventional treatment Arm
Refractory cardiogenic shock defined as
Mandatory validation of rescue VA-ECMO by an independent adjudicator.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Altered mental status OR cold, clammy skin and extremities OR oliguria with urine output \<30 ml/h OR serum lactate >2.0 mmol/l
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
VA-ECMO will be instituted percutaneously under echo guidance via the femoral route as soon as possible. An IABP will be systematically inserted in the contralateral femoral artery (unless technically not possible).
Device: VA-ECMO
Standard management of cardiogenic shock due to myocardial infarction according to the current ESC guidelines. It is not recommended to use IABP support and no other TCS device (e.g., ECMO, Impella, Thoratec PHP, TandemHeart) will be permitted in the control group.
* The ECMO device will be the CardioHelp (MAQUET, GETINGE, Orléans, France) using the veno-arterial setting and percutaneous femoro-femoral cannulation with MAQUET GETINGE HLS cannulae. * Intraortic balloon pump will be MEGA 50 cc or 40cc, (MAQUET, GETINGE, Orléans, France).
Treatment failure at Day 30
Death in the ECMO group and death OR rescue ECMO in the control group
Time frame: At day 30
Mortality at Day 30
All-cause mortality at day 30
Time frame: At day 30
Major Adverse Cardiovascular Events
Major Adverse Cardiovascular Events are defined as death, stroke (any new neurological symptoms in association with signs of ischemia or hemorrhage in a cranial CT or MRI), recurrent myocardial infarction, need for repeat revascularization (PCI and/or CABG), renal replacement therapy, re-hospitalization for heart failure, escalation to permanent left ventricular assist device (LVAD) or total artificial heart, cardiac transplant.
Time frame: At day 30
Stroke
Any new neurological symptoms in association with signs of ischemia or hemorrhage in a cranial CT or MRI
Time frame: At day 30
Recurrent myocardial infarction
Recurrent myocardial infarction
Time frame: At day 30
Need for repeat revascularization with PCI and/or CABG
Need for repeat revascularization (PCI and/or CABG)
Time frame: At day 30
Need for renal replacement therapy
Need for renal replacement therapy
Time frame: At day 30
Re-hospitalization for heart failure
re-hospitalization for heart failure
Time frame: At day 30
Escalation to LVAD or total artificial heart
Escalation to permanent left ventricular assist device or total artificial heart
Time frame: At day 30
Cardiac transplantation
Cardiac transplantation
Time frame: At day 30
Major bleeding
Major bleeding (TIMI definition): Any intracranial bleeding (excluding microhemorrhages \<10 mm evident only on gradient-echo MRI) OR Clinically overt signs of hemorrhage associated with a drop in hemoglobin of ≥5 g/dL or a ≥15% absolute decrease in hematocrit OR Fatal bleeding (bleeding that directly results in death within 7 d)
Time frame: At day 30
Red blood cells transfused
Number of packed red blood cells transfused
Time frame: At day 30
Serum lactate
Time to serum lactate normalization
Time frame: At day 30
Number of days alive without organ failure at day 30
Number of days alive without organ failure(s) defined with the SOFA score, catecholamine support, mechanical ventilation and renal replacement therapy
Time frame: At day 30
Durations of ICU stay and hospitalization
Durations of ICU stay and of hospitalization
Time frame: At day 30
LV function
LV function assessed with Doppler echocardiography or magnetic resonance imaging
Time frame: At day 30
NYHA/INTERMACS status
NYHA/INTERMACS status
Time frame: At day 30
ECMO-related complications
ECMO-related complications (infection at VA-ECMO cannulation sites requiring antibiotics, hemorrhage, limb ischemia requiring surgery, cannula or circuit thrombosis, overt pulmonary edema, thrombocytopenia, gaseous emboli and hemolysis).
Time frame: At day 30
Treatment failure at one year
Treatment failure defined as death (all-cause) in the ECMO group and death (all-cause) OR rescue ECMO in the control group.
Time frame: At one year
Mortality at one year
All-cause mortality
Time frame: At one year
Major Adverse Cardiovascular at one year
MACE, Major Adverse Cardiovascular Events are defined as death, stroke (any new neurological symptoms in association with signs of ischemia or hemorrhage in a cranial CT or MRI), recurrent myocardial infarction, need for repeat revascularization (PCI and/or CABG), renal replacement therapy, re-hospitalization for heart failure, escalation to permanent left ventricular assist device (LVAD) or total artificial heart, cardiac transplant.
Time frame: At one year
Stroke at one year
Stroke (any new neurological symptoms in association with signs of ischemia or hemorrhage in a cranial CT or MRI),
Time frame: At one year
Recurrent myocardial infarction at one year
Recurrent myocardial infarction between randomization and one year
Time frame: At one year
PCI and/or CABG at one year
Repeat revascularization (PCI and/or CABG) between randomization and one year
Time frame: At one year
Renal replacement therapy at one year
Need for renal replacement therapy between randomization and one year
Time frame: At one year
Re-hospitalization for heart failure
Re-hospitalization for heart failure between randomization and one year
Time frame: At one year
LVAD at one year
Escalation to permanent left ventricular assist device (LVAD) or total artificial heart
Time frame: At one year
Cardiac transplant at one year
Cardiac transplantation
Time frame: At one year
Major bleeding at one year
Major bleeding (TIMI definition): Any intracranial bleeding (excluding microhemorrhages \<10 mm evident only on gradient-echo MRI) OR Clinically overt signs of hemorrhage associated with a drop in hemoglobin of ≥5 g/dL or a ≥15% absolute decrease in hematocrit OR Fatal bleeding (bleeding that directly results in death within 7 d)
Time frame: At one year
NYHA/INTERMACS status at one year
NYHA/INTERMACS status
Time frame: At one year
Returned to work at one year
Rate of patients who returned to work if previously active
Time frame: At one year
LV ejection fraction at one year
Latest LV ejection fraction
Time frame: At one year
Short Form 36 (SF-36) questionnaire at one year
Quality of life assessed using the Short Form 36 (SF-36) Health Survey questionnaire
Time frame: At one year
Plan to share: No
Started Oct 2021 (actual). Primary completion is estimated for Oct 2026, 60 months after the start.
Of 48 non-industry interventional studies with no phase under Shock, Cardiogenic, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 55. This study's planned 60 months is above that.
Counting every sponsor, half of 52 studies reached it within 39 months; a quarter within 24 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →